Nationwide Fund Advisors’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-39,910
Closed -$3.07M 1663
2017
Q3
$3.07M Sell
39,910
-199,749
-83% -$15.3M 0.01% 1260
2017
Q2
$18.7M Buy
239,659
+3,148
+1% +$225K 0.07% 343
2017
Q1
$17M Buy
236,511
+2,477
+1% +$171K 0.07% 391
2016
Q4
$14.5M Sell
234,034
-3,209
-1% -$197K 0.06% 439
2016
Q3
$15.4M Sell
237,243
-619
-0.3% -$41.2K 0.06% 414
2016
Q2
$15M Buy
237,862
+6,616
+3% +$390K 0.07% 405
2016
Q1
$13.4M Buy
231,246
+7,290
+3% +$413K 0.06% 442
2015
Q4
$12M Sell
223,956
-245
-0.1% -$13.8K 0.05% 485
2015
Q3
$11.4M Sell
224,201
-940
-0.4% -$50.6K 0.05% 471
2015
Q2
$12.7M Sell
225,141
-5,299
-2% -$334K 0.05% 460
2015
Q1
$16.5M Buy
230,440
+2,655
+1% +$172K 0.07% 371
2014
Q4
$12.8M Sell
227,785
-120,700
-35% -$6.3M 0.05% 450
2014
Q3
$17.2M Buy
348,485
+6,549
+2% +$334K 0.07% 329
2014
Q2
$17.3M Sell
341,936
-12,589
-4% -$624K 0.07% 354
2014
Q1
$15.8M Buy
354,525
+61,456
+21% +$2.76M 0.07% 338
2013
Q4
$13.8M Buy
293,069
+40,542
+16% +$2.05M 0.06% 416
2013
Q3
$13.3M Buy
252,527
+6,495
+3% +$315K 0.06% 399
2013
Q2
$11.1M Buy
+246,032
New +$11.7M 0.06% 403

Other funds holding RMD

Nationwide Fund Advisors's RMD Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of ResMed (RMD) in Q4 2017, closing a stake of 39,910 shares — an estimated $3.07M sold.

Nationwide Fund Advisors first reported a position in RMD in Q2 2013 and held it in 18 quarters. The position peaked at $18.7M in Q2 2017. 415 funds tracked by Wall St. Rank hold RMD as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining ResMed position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 39,910 ResMed shares in Q4 2017, an estimated $3.07M.
  • Nationwide Fund Advisors first reported a position in ResMed in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's ResMed position peaked at $18.7M in Q2 2017.
  • 415 funds tracked by Wall St. Rank held ResMed as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.